Identification

Name
Dantrolene
Accession Number
DB01219  (APRD00901)
Type
Small Molecule
Groups
Approved, Investigational
Description

Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.

Structure
Thumb
Synonyms
  • Dantamacrin
  • Dantrolene
  • Dantroleno
  • Dantrolenum
  • F-368
Product Ingredients
IngredientUNIICASInChI Key
Dantrolene Sodium287M0347EV24868-20-0OZOMQRBLCMDCEG-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DantriumInjection20 mg/60mLIntravenousPar Pharmaceutical2008-08-01Not applicableUs
DantriumCapsule25 mg/1OralPar Pharmaceutical2008-08-01Not applicableUs
DantriumCapsule100 mg/1OralPar Pharmaceutical2008-08-012017-05-10Us
DantriumCapsule50 mg/1OralPar Pharmaceutical2008-08-01Not applicableUs
Dantrium Cap 100mgCapsule100 mgOralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium Cap 25mgCapsule25 mgOralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium CapsulesCapsule100 mgOralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium CapsulesCapsule25 mgOralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium IntravenousPowder, for solution20 mgIntravenousEndo Par Innovaton Company, Llc1993-12-31Not applicableCanada
Ryanodex Dantrolene SodiumInjection, suspension250 mg/5mLIntravenousEagle Pharmaceuticals, Inc.2014-07-23Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DantroleneInjection, powder, for solution20 mg/1IntravenousWest Ward Pharmaceutical2017-06-19Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralAmerincan Health Packaging2008-09-25Not applicableUs
Dantrolene SodiumCapsule50 mg/1OralImpax Generics2005-03-01Not applicableUs
Dantrolene SodiumCapsule100 mg/1OralPar Pharmaceutical2016-02-19Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralPar Pharmaceutical2013-04-08Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralImpax Generics2005-03-01Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralCarilion Materials Management2005-03-01Not applicableUs
Dantrolene SodiumCapsule50 mg/1OralPar Pharmaceutical2016-02-19Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralCardinal Health2008-09-25Not applicableUs
Dantrolene SodiumCapsule100 mg/1OralImpax Generics2005-03-01Not applicableUs
International/Other Brands
Dantamacrin (Spepharm) / Dantrium
Categories
UNII
F64QU97QCR
CAS number
7261-97-4
Weight
Average: 314.253
Monoisotopic: 314.06511945
Chemical Formula
C14H10N4O5
InChI Key
OZOMQRBLCMDCEG-VIZOYTHASA-N
InChI
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
IUPAC Name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
SMILES
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O

Pharmacology

Indication

For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.

Associated Conditions
Pharmacodynamics

Dantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that “triggering agents” (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the “triggered” malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm.

Mechanism of action

Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.

TargetActionsOrganism
ARyanodine receptor 1
antagonist
Human
Absorption

Bioavailability is 70%.

Volume of distribution
Not Available
Protein binding

Significant, mostly to albumin.

Metabolism

Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.

Route of elimination
Not Available
Half life

The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.

Clearance
Not Available
Toxicity

Oral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Dantrolene can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dantrolene.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Amperozide.Experimental
ApalutamideThe serum concentration of Dantrolene can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Dantrolene can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene.Approved
AtazanavirThe metabolism of Dantrolene can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Azaperone.Investigational, Vet Approved
AzelastineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dantrolene.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dantrolene is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Dantrolene can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Dantrolene can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dantrolene can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Bupivacaine.Approved, Investigational
BuprenorphineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dantrolene.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dantrolene is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Dantrolene is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Dantrolene can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dantrolene is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.Approved
CeritinibThe serum concentration of Dantrolene can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dantrolene.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dantrolene.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.Approved
ClarithromycinThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dantrolene can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dantrolene.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dantrolene.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Dantrolene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.Approved
CobicistatThe metabolism of Dantrolene can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Dantrolene.Approved, Investigational
CrizotinibThe metabolism of Dantrolene can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Dantrolene can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.Approved
DabrafenibThe serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Dantrolene can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dantrolene can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Dantrolene.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dantrolene.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dantrolene is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.Approved, Illicit
DihydroergotamineThe metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDantrolene may increase the hyperkalemic activities of Diltiazem.Approved, Investigational
DiltiazemThe metabolism of Dantrolene can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.Approved, Investigational
DoxycyclineThe metabolism of Dantrolene can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dantrolene is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Illicit
DronedaroneThe metabolism of Dantrolene can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dantrolene.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.Approved, Investigational
EnzalutamideThe serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Dantrolene can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dantrolene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.Approved, Investigational
EthanolDantrolene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dantrolene.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Dantrolene can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dantrolene.Approved
FluvoxamineThe metabolism of Dantrolene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dantrolene can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dantrolene can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dantrolene can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Dantrolene can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dantrolene is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dantrolene.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Dantrolene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Hexobarbital.Approved
HydrocodoneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
IdelalisibThe metabolism of Dantrolene can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.Approved
ImatinibThe metabolism of Dantrolene can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Dantrolene can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indiplon.Investigational
IsavuconazoleThe serum concentration of Dantrolene can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Dantrolene can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dantrolene.Approved, Vet Approved
IsradipineThe metabolism of Dantrolene can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Dantrolene can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dantrolene can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Dantrolene can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Lidocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Dantrolene is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Dantrolene is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Dantrolene can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Dantrolene can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dantrolene.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Dantrolene can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Dantrolene can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.Approved
LuliconazoleThe serum concentration of Dantrolene can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dantrolene can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Dantrolene can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Dantrolene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dantrolene.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dantrolene is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.Approved
MethotrimeprazineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methylphenobarbital.Approved
MetyrosineDantrolene may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.Approved, Illicit
MifepristoneThe serum concentration of Dantrolene can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
MirtazapineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Dantrolene can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.Approved
NefazodoneThe metabolism of Dantrolene can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dantrolene can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dantrolene can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Dantrolene can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Dantrolene can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dantrolene.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dantrolene.Approved, Investigational
OlaparibThe metabolism of Dantrolene can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dantrolene is combined with Opium.Approved, Illicit
OrphenadrineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dantrolene is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dantrolene can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.Approved
OxprenololThe risk or severity of adverse effects can be increased when Dantrolene is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.Approved
ParaldehydeDantrolene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.Approved, Vet Approved
PentobarbitalThe metabolism of Dantrolene can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
PerazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dantrolene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dantrolene is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Dantrolene can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Dantrolene can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Dantrolene can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Dantrolene can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleDantrolene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Dantrolene can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Prilocaine.Approved
PrimidoneThe metabolism of Dantrolene can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Dantrolene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dantrolene is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.Approved, Investigational
RanolazineThe metabolism of Dantrolene can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.Approved, Investigational
RifabutinThe metabolism of Dantrolene can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Dantrolene can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dantrolene can be increased when combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Romifidine.Vet Approved
RopiniroleDantrolene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ropivacaine.Approved
RotigotineDantrolene may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Dantrolene can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene.Approved
SaquinavirThe metabolism of Dantrolene can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Dantrolene can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.Approved, Vet Approved
SildenafilThe metabolism of Dantrolene can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dantrolene can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Dantrolene can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
St. John's WortThe serum concentration of Dantrolene can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Dantrolene can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.Approved, Investigational
SulfisoxazoleThe metabolism of Dantrolene can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sultopride.Experimental
SuvorexantDantrolene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tasimelteon.Approved, Investigational
TelaprevirThe metabolism of Dantrolene can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Dantrolene can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrodotoxin.Investigational
ThalidomideDantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dantrolene is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Dantrolene can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.Approved, Investigational
TocilizumabThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Dantrolene is combined with Valproic Acid.Approved, Investigational
VecuroniumDantrolene may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe serum concentration of Dantrolene can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Dantrolene can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Veralipride.Experimental
VerapamilDantrolene may increase the hyperkalemic activities of Verapamil.Approved
VerapamilThe metabolism of Dantrolene can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dantrolene.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Dantrolene can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dantrolene can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zolazepam.Vet Approved
ZolpidemDantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dantrolene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Davis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.

General References
  1. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108]
External Links
KEGG Drug
D02347
KEGG Compound
C06939
PubChem Compound
6914273
PubChem Substance
46504976
ChemSpider
5290202
ChEBI
4317
ChEMBL
CHEMBL1201288
Therapeutic Targets Database
DNC001623
PharmGKB
PA449208
IUPHAR
4172
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dantrolene
ATC Codes
M03CA01 — Dantrolene
AHFS Codes
  • 12:20.08 — Direct-acting Skeletal Muscle Relaxants
MSDS
Download (43 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentCerebral Vasospasm After Subarachnoid Hemorrhage1
1, 2CompletedTreatmentCerebral Vasospasm / Subarachnoid Hemorrhage1
1, 2RecruitingTreatmentAtaxia / Diabetes Mellitus (DM) / Optic Nerve Atrophy / Wolfram Syndrome1
2, 3TerminatedTreatmentHyperthermia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amerisource Health Services Corp.
  • DSM Corp.
  • Global Pharmaceuticals
  • JHP Pharmaceuticals LLC
  • Kaiser Foundation Hospital
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Norwich Pharmaceuticals Inc.
  • Southwood Pharmaceuticals
  • US WorldMeds
  • Warner Chilcott Co. Inc.
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral50 mg/1
InjectionIntravenous20 mg/60mL
CapsuleOral100 mg
CapsuleOral25 mg
Powder, for solutionIntravenous20 mg
Injection, powder, for solutionIntravenous20 mg/1
CapsuleOral25 mg/1
Injection, powder, lyophilized, for solutionIntravenous20 mg/60mL
Injection, suspensionIntravenous250 mg/5mL
Prices
Unit descriptionCostUnit
Dantrium 20 mg vial106.37USD vial
Dantrolene sodium 20 mg vial97.2USD vial
Dantrolene sodium powder17.6USD g
Dantrium 100 mg capsule2.4USD capsule
Dantrolene sodium 100 mg capsule2.03USD capsule
Dantrium 50 mg capsule1.93USD capsule
Dantrolene sodium 50 mg capsule1.63USD capsule
Dantrium 25 mg capsule1.29USD capsule
Dantrolene sodium 25 mg capsule1.09USD capsule
Dantrium 100 mg Capsule0.8USD capsule
Dantrium 25 mg Capsule0.4USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8685460No2003-02-152023-02-15Us
US7758890No2005-07-012025-07-01Us
US8110225No2002-12-242022-12-24Us
US8604072No2002-12-242022-12-24Us
US9884044No2002-06-132022-06-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)279-280 °CDavis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.
water solubilityLow (146 mg/L)Not Available
logP1.70JANSEN,ACA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.0805 mg/mLALOGPS
logP1.65ALOGPS
logP1.26ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.23ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.73 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.87 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9581
Caco-2 permeable-0.5587
P-glycoprotein substrateNon-substrate0.6562
P-glycoprotein inhibitor INon-inhibitor0.8977
P-glycoprotein inhibitor IINon-inhibitor0.978
Renal organic cation transporterNon-inhibitor0.8656
CYP450 2C9 substrateNon-substrate0.81
CYP450 2D6 substrateNon-substrate0.8935
CYP450 3A4 substrateSubstrate0.5848
CYP450 1A2 substrateInhibitor0.8916
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9203
CYP450 2C19 inhibitorNon-inhibitor0.8752
CYP450 3A4 inhibitorNon-inhibitor0.8985
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7676
Ames testAMES toxic0.8925
CarcinogenicityNon-carcinogens0.8732
BiodegradationReady biodegradable0.5901
Rat acute toxicity2.5390 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7215
hERG inhibition (predictor II)Non-inhibitor0.9223
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Hydantoins
Alternative Parents
Alpha amino acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Semicarbazones / Dicarboximides / Furans / Heteroaromatic compounds / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds
show 7 more
Substituents
Hydantoin / Alpha-amino acid or derivatives / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Semicarbazone / Benzenoid / Heteroaromatic compound / Dicarboximide / Furan
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
hydrazone, imidazolidine-2,4-dione (CHEBI:4317)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tu...
Gene Name
RYR1
Uniprot ID
P21817
Uniprot Name
Ryanodine receptor 1
Molecular Weight
565170.715 Da
References
  1. Britt BA, Scott E, Frodis W, Clements MJ, Endrenyi L: Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle. Can Anaesth Soc J. 1984 Mar;31(2):130-54. [PubMed:6704779]
  2. Harrison GG: Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975. Br J Anaesth. 1998 Oct;81(4):626-9; discussion 625. [PubMed:9924249]
  3. Flewellen EH, Nelson TE: Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Anesthesiology. 1980 Apr;52(4):303-8. [PubMed:7362049]
  4. Tonner PH, Scholz J, Richter A, Loscher W, Steinfath M, Wappler F, Wlaz P, Hadji B, Roewer N, Schulte am Esch J: Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. Br J Anaesth. 1995 Oct;75(4):467-71. [PubMed:7488490]
  5. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J: Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem. 2006 Nov 3;281(44):33477-86. Epub 2006 Aug 31. [PubMed:16945924]
  6. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108]
  7. Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F: [Dantrolene. Pharmacological and therapeutic aspects]. Anaesthesist. 2003 Mar;52(3):238-45. [PubMed:12666006]
  8. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002 Sep 20;277(38):34918-23. Epub 2002 Jul 11. [PubMed:12167662]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:07